A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

@article{Clarke2003ANF,
  title={A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition},
  author={A. Clarke and F. Brewer and E. Johnson and N. Mallard and F. Hartig and S. Taylor and T. Corn},
  journal={Journal of Neural Transmission},
  year={2003},
  volume={110},
  pages={1241-1255}
}
  • A. Clarke, F. Brewer, +4 authors T. Corn
  • Published 2003
  • Chemistry, Medicine
  • Journal of Neural Transmission
    • Summary. Seven randomised comparative studies were conducted in healthy volunteers to compare the pharmacokinetic and pharmacodynamic profiles of selegiline hydrochloride in a new formulation designed for buccal absorption “Zydis Selegiline” (1.25–10 mg) with conventional selegiline hydrochloride tablets “conventional selegiline tablets” (10 mg). A total of 156 healthy volunteers participated in these studies. Plasma concentrations of selegiline and its primary metabolites, N… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    126 Citations
    Highly Influential Citations
    11
    Background Citations
    42
    Methods Citations
    10
    Results Citations
    4
    126 Citations
    Citation Type

    Citation Type

    A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
    • 53
    Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
    • 34
    • Highly Influenced
    • PDF
    Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors
    • 43
    Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
    • 1
    Selegiline: a molecule with innovative potential
    • 5
    • PDF
    A novel formulation of selegiline for the treatment of Parkinson’s disease
    • 17
    The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease
    • 12
    • Highly Influenced
    • PDF
    Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease
    • 60
    Novel Spectrophotometric Methods for the Determination of Selegiline Hydrochloride in Bulk and Its Pharmaceutical Preparation
    • 3
    • PDF
    Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

    References

    SHOWING 1-10 OF 29 REFERENCES
    Clinical Pharmacokinetics and Pharmacodynamics of Selegiline
    • 96
    The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    • 18
    • Highly Influential
    Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
    • 285
    Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
    • 77
    • Highly Influential
    The molecular pharmacology of L-deprenyl.
    • 97
    R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    • J. Knoll
    • Chemistry, Medicine
    • Journal of neural transmission. Supplementum
    • 1987
    • 111
    Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
    • 144
    Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo
    • 117
    Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl
    • 244
    CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
    • 90
    • PDF